Faculty Profiles - HATTORI Norifumi

Papers - HATTORI Norifumi

Division display 141 - 160 of about 220 ／ All the affair displays >>

骨盤内臓全摘術後のサルコペニア内腸骨動脈血管処理に着目して

村田悠記, 上原圭, 相場利貞, 小倉淳司, 大原規彰, 神野孝徳, 三品拓也, 鈴木優美, 服部憲史, 中山吾郎, 横山幸浩, 伊神剛, 深谷昌秀, 水野隆史, 山口淳平, 宮田一志, 尾上俊介, 渡辺伸元, 小寺泰弘, 江畑智希

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 4 2021.4

直腸癌同時性肝転移に対する手術治療戦略

米川佳彦, 上原圭, 相場利貞, 小倉淳司, 大原規彰, 村田悠記, 神野孝徳, 鈴木優美, 三品拓也, 服部憲史, 中山吾郎, 横山幸浩, 伊神剛, 深谷昌秀, 水野隆史, 山口淳平, 宮田一志, 尾上俊介, 小寺泰弘, 江畑智希

日本外科学会定期学術集会抄録集 Vol. 121回 page： PS - 8 2021.4

進行再発大腸癌における3次治療以降の予後予測因子の検討

神野孝徳, 上原圭, 相場利貞, 小倉淳司, 大原規彰, 村田悠記, 鈴木優美, 三品拓也, 服部憲史, 中山吾郎, 横山幸浩, 伊神剛, 深谷昌秀, 水野隆史, 山口淳平, 宮田一志, 尾上俊介, 渡辺伸元, 小寺泰弘, 江畑智希

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 7 2021.4

進行再発大腸癌に対する集学的アプローチの最先端結腸癌非肝肺転移に対する外科切除の意義

三品拓也, 上原圭, 相場利貞, 小倉淳司, 大原規彰, 村田悠記, 神野孝徳, 鈴木優美, 服部憲史, 中山吾郎, 横山幸浩, 伊神剛, 深谷昌秀, 水野隆史, 山口淳平, 宮田一志, 尾上俊介, 渡辺伸元, 小寺泰弘, 江畑智希

日本外科学会定期学術集会抄録集 Vol. 121回 page： WS - 2 2021.4

局所進行直腸癌における術前化学療法後の病理学的リンパ節転移奏功度の意義

相場利貞, 上原圭, 小倉淳司, 大原規彰, 神野孝徳, 鈴木優美, 三品拓也, 村田悠記, 渡辺伸元, 尾上俊介, 宮田一志, 山口淳平, 水野隆史, 深谷昌秀, 伊神剛, 服部憲史, 中山吾郎, 横山幸浩, 小寺泰弘, 江畑智希

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 5 2021.4

下部直腸癌術後患者の長期腎機能へ影響を与える因子の検討

山東雅紀, 上原圭, 相場利貞, 小倉淳司, 大原規彰, 村田悠記, 三品拓也, 服部憲史, 中山吾郎, 横山幸浩, 伊神剛, 深谷昌秀, 水野隆, 山口淳平, 宮田一志, 尾上俊介, 渡辺伸元, 川井覚, 小寺泰弘, 江畑智希

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 5 2021.4

再発大腸癌における予後予測マーカーとしてのCEA比の有用性

鈴木優美, 小倉淳司, 上原圭, 相場利貞, 大原規彰, 村田悠記, 神野孝徳, 三品拓也, 服部憲史, 中山吾郎, 横山幸浩, 伊神剛, 深谷昌秀, 水野隆史, 山口淳平, 宮田一志, 尾上俊介, 渡辺伸元, 小寺泰弘, 江畑智希

日本外科学会定期学術集会抄録集 Vol. 121回 page： PS - 1 2021.4

大腸癌術後ストマ造設症例における腹壁瘢痕および傍ストマヘルニアの因果関係

大原規彰, 上原圭, 相場利貞, 小倉淳司, 村田悠記, 神野孝徳, 三品拓也, 佐藤雄介, 服部憲史, 中山吾郎, 横山幸浩, 伊神剛, 深谷昌秀, 水野隆史, 山口淳平, 宮田一志, 尾上俊介, 渡辺伸元, 小寺泰弘, 江畑智希

日本外科学会定期学術集会抄録集 Vol. 121回 page： SF - 8 2021.4

ETNK2のアポトーシス調整を介した胃癌肝転移形成との関連性(ETNK2 promotes hepatic metastasis of gastric cancer via the p53-Bcl-2 related apoptosis)

三輪高嗣, 神田光郎, 田中千恵, 清水大, 園原史訓, 高見秀樹, 猪川祥邦, 服部憲史, 林真路, 山田豪, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本胃癌学会総会記事 Vol. 93回 page： 244 - 244 2021.3

直腸がんの治療戦略-内視鏡外科をどう活かすか? 骨盤拡大手術における内視鏡外科手術での後腹膜アプローチ

上原圭, 相場利貞, 小倉淳司, 村田悠記, 松村卓樹, 三品拓也, 大原規彰, 鈴木優美, 伊神剛, 水野隆史, 宮田一志, 服部憲史, 中山吾郎, 小寺泰弘, 江畑智希

日本内視鏡外科学会雑誌 Vol. 25 ( 7 ) page： SSY5 - 3 2021.3

直腸がんの治療戦略-内視鏡外科をどう活かすか? 骨盤拡大手術における内視鏡外科手術での後腹膜アプローチ

日本内視鏡外科学会雑誌 Vol. 25 ( 7 ) page： SSY5 - 3 2021.3

Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study). Reviewed International journal

Goro Nakayama, Nao Takano, Hiroya Taniguchi, Kiyoshi Ishigure, Hiroyuki Yokoyama, Hitoshi Teramoto, Ryoji Hashimoto, Mitsuru Sakai, Akiharu Ishiyama, Takashi Kinoshita, Naomi Hayashi, Masanori Nakamura, Norifumi Hattori, Yusuke Sato, Shinichi Umeda, Kei Uehara, Toshisada Aiba, Fuminori Sonohara, Masamichi Hayashi, Mitsuro Kanda, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Masahiko Koike, Michitaka Fujiwara, Kenta Murotani, Masahiko Ando, Yuichi Ando, Kei Muro, Yasuhiro Kodera

European journal of cancer (Oxford, England : 1990) Vol. 144 page： 61 - 71 2021.2

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Peripheral sensory neuropathy (PSN) caused by oxaliplatin-based adjuvant chemotherapy adversely affects patients' quality of life. This study evaluated the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) with intermittent oxaliplatin use compared with the standard CAPOX in adjuvant therapy for colon cancer. PATIENTS AND METHODS: Patients with curative resection for stage II/III colon cancer were randomly assigned to receive either CAPOX with continuous oxaliplatin (eight cycles of CAPOX) or CAPOX with intermittent oxaliplatin (two cycles of CAPOX, four cycles of capecitabine and two cycles of CAPOX). The primary end-point was the 1-year PSN rate, and the key secondary end-point was disease-free survival (DFS). RESULTS: Two hundred patients were enrolled in the intent-to-treat population. After 4 patients withdrew, 196 patients were included in the safety analysis. The overall treatment completion rate was 65% for continuous vs. 89% for intermittent treatment (p < 0.001). The 1-year PSN rate was 60% (95% confidence interval [CI], 50%-70%) for continuous and 16% (95% CI, 10%-25%) for intermittent treatment (p < 0.001). After a median follow-up of 52 months, 40 events (20%) were observed. The 3-year DFS was 81% (95% CI, 71%-87%) for continuous and 84% (95% CI, 75%-90%) for intermittent treatment (hazard ratio [HR], 0.87; 95% CI, 0.47-1.63). Among patients with high-risk disease (T4 or N2-3), the 3-year DFS was 57% for continuous vs. 74% for intermittent treatment (HR, 0.66). CONCLUSION: CAPOX with planned intermittent oxaliplatin may be feasible as an adjuvant therapy for colon cancer and substantially reduce the duration of long-lasting PSN. TRIAL IDENTIFIER: UMIN000012535.

DOI： 10.1016/j.ejca.2020.11.007

Web of Science

PubMed

Tissue RNFT2 Expression Levels Are Associated With Peritoneal Recurrence and Poor Prognosis in Gastric Cancer. Reviewed International journal

Masahiro Sasahara, Mitsuro Kanda, Dai Shimizu, Chie Tanaka, Yoshikuni Inokawa, Norifumi Hattori, Masamichi Hayashi, Goro Nakayama, Yasuhiro Kodera

Anticancer research Vol. 41 ( 2 ) page： 609 - 617 2021.2

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND/AIM: Disease recurrence is frequently observed after curative resection of advanced gastric cancer resulting in a poor prognosis. In the present study, we identified a candidate biomarker to predict recurrence and prognosis after curative resection of gastric cancer. MATERIALS AND METHODS: A transcriptome analysis was conducted using surgically resected cancerous tissue from patients with metastatic gastric cancer to identify genes that are upregulated in primary and metastatic tissues. RESULTS: Ring finger protein, transmembrane 2 (RNFT2) mRNA expression was upregulated in primary gastric cancer tissues and metastases compared with non-cancerous tissues. RNFT2 expression in gastric cancer cell lines was positively correlated with the EMT-related molecules GSC, MMP9, and RAC1. The RNFT2 high expression group exhibited a significantly shorter postoperative overall survival. Peritoneal recurrence was significantly higher in the RNFT2 high expression group. CONCLUSION: RNFT2 mRNA expression predicts peritoneal recurrence and is a potential prognostic biomarker for gastric cancer following curative gastrectomy.

DOI： 10.21873/anticanres.14812

Web of Science

PubMed

Fuminori Sonohara, Suguru Yamada, Keisuke Kurimoto, Yoshikuni Inokawa, Hideki Takami, Masamichi Hayashi, Dai Shimizu, Norifumi Hattori, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Tsutomu Fujii, Yasuhiro Kodera

Pancreas Vol. 50 ( 1 ) page： 37 - 46 2021.1

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVES: In this study, we retrospectively assessed the feasibility and prognostic efficacy of perioperative chemo(radio)therapy for pancreatic cancer (PC) patients according to age. METHODS: A total of 556 consecutive patients who underwent curative-intent pancreatectomy for PC between 2000 and 2018 were enrolled. RESULTS: Of the 556 patients who underwent resection, 95 (17%) were elderly (age, ≥75 years). Postoperative complications did not significantly differ between the 2 age groups, and postoperative prognoses were also similar (recurrence-free survival [RFS], P = 0.68; overall survival [OS], P = 0.28). In this cohort, 103 patients (19%) underwent preoperative chemo(radio)therapy, and 417 (77%) underwent postoperative chemotherapy. Perioperative therapy was found to be significantly beneficial for younger patients (preoperative therapy: RFS, P = 0.006; OS, P < 0.001; postoperative therapy: RFS, P < 0.001; OS, P < 0.001). Conversely, no significant survival benefit of perioperative therapy was found for the elderly (preoperative therapy: RFS, P = 0.28; OS, P = 0.44; postoperative therapy: RFS, P = 0.77; OS, P = 0.08). CONCLUSIONS: This study demonstrated that, although perioperative therapy is feasible for selected elderly patients with PC, this approach might not be as beneficial as it is for younger PC patients.

DOI： 10.1097/MPA.0000000000001712

Web of Science

PubMed

Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus. Reviewed

Dai Shimizu, Masahiko Koike, Mitsuro Kanda, Fuminori Sonohara, Norifumi Hattori, Masamichi Hayashi, Chie Tanaka, Suguru Yamada, Yasuhiro Kodera

Surgery today Vol. 51 ( 1 ) page： 153 - 158 2021.1

Language：English Publishing type：Research paper (scientific journal)

PURPOSE: We evaluated the efficacy of the long-term follow-up of patients who underwent radical esophagectomy for esophageal squamous cell carcinoma (ESCC) to screen for recurrence and new primary malignancies. METHODS: We retrospectively collected 448 ESCC patients who underwent radical esophagectomy. Esophagogastroduodenoscopy, computed tomography, a stool test and the assessment of the serum concentration of squamous cell carcinoma antigen and carcinoembryonic antigen were performed annually, even over 5 years after esophagectomy. The incidence of ESCC recurrence and new primary malignancies was investigated. RESULTS: We enrolled 222 patients who survived at least 5 years after esophagectomy. A total of 104 new primary malignancies occurred in 82 patients (36.9%) after esophagectomy. Twenty-one malignancies were in the head and neck region, 14 in the residual esophagus, 13 in the prostate and 11 in the gastric tube and lung. Patients who developed new primary malignancies after esophagectomy had a significantly higher Brinkman index than those without new malignancies. An endoscopic approach successfully treated 92.9% of carcinomas in the residual esophagus, 90.9% of cancers in the gastric tube and 42.9% of carcinomas in the head and neck region. CONCLUSION: The incidence of new primary malignancies was higher than the age-standardized incidence. Long-term follow-up and systemic screening may increase the probability of an early diagnosis and subsequent low-invasive treatment.

DOI： 10.1007/s00595-020-02072-w

Web of Science

PubMed

消化管腫瘍の新展開進行消化管癌における集学的治療の実際と課題局所進行直腸癌に対する術前化学療法の効果と限界

上原圭, 相場利貞, 小倉淳司, 大原規彰, 神野孝徳, 村田悠記, 三品拓也, 鈴木優美, 佐藤雄介, 服部憲史, 中山吾郎, 横山幸浩, 國料俊男, 伊神剛, 深谷昌秀, 水野隆史, 山口淳平, 宮田一志, 小寺泰弘, 江畑智希

日本消化管学会雑誌 Vol. 5 ( Suppl. ) page： 142 - 142 2021.1

AMIGO2 Expression as a Potential Prognostic Biomarker for Gastric Cancer. International journal

Shunsuke Nakamura, Mitsuro Kanda, Dai Shimizu, Chie Tanaka, Yoshikuni Inokawa, Norifumi Hattori, Masamichi Hayashi, Suguru Yamada, Goro Nakayama, Kenji Omae, Masahiko Koike, Yasuhiro Kodera

Anticancer research Vol. 40 ( 12 ) page： 6713 - 6721 2020.12

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND/AIM: Although our understanding of the molecular mechanisms of gastric cancer (GC) development and progression is steadily deepening, the clinical outcome of GC patients remains inadequate. The identification of molecules associated with GC will help improve prognosis. We aimed to identify the molecules involved in GC progression and metastasis. MATERIALS AND METHODS: Transcriptome analysis was performed on surgically resected gastric tissue from patients with hepatic metastasis. Fourteen cell lines and 230 pairs of primary GC tissues and their corresponding normal adjacent tissues were included in the mRNA expression analysis. RESULTS: Adhesion molecule with Ig like domain 2 (AMIGO2) was identified as a gene of interest. The levels of AMIGO2 mRNA positively correlated with those encoding FOXC2, NODAL, GEMIN2 and negatively correlated with TFPI2. Patients with high AMIGO2 expression experienced significantly shorter disease-free survival and overall survival. High levels of AMIGO2 were associated with poor prognosis. CONCLUSION: Patients with GC with high AMIGO2 mRNA levels experienced significantly shorter survival, suggesting that AMIGO2 may serve as a prognostic biomarker for GC.

DOI： 10.21873/anticanres.14694

Web of Science

PubMed

下部進行直腸癌における側方リンパ節に対する術前化学療法の治療効果と限界

小倉淳司, 上原圭介, 相場利貞, 佐藤雄介, 服部憲史, 中山吾郎, 江畑智希, 小寺泰弘, 梛野正人

日本消化器外科学会総会 Vol. 75回 page： O6 - 4 2020.12

当院における進行再発大腸癌に対するFOLFIRI+Ramucirumab投与症例の検討

村田悠記, 上原圭介, 相場利貞, 小倉淳司, 佐藤雄介, 中山吾郎, 服部憲史, 江畑智希, 小寺泰弘, 梛野正人

日本消化器外科学会総会 Vol. 75回 page： P127 - 5 2020.12

当院における進行再発大腸癌に対するAflibercept治療成績の検討

大原規彰, 上原圭介, 相場利貞, 小倉淳司, 佐藤雄介, 中山吾郎, 服部憲史, 江畑智希, 小寺泰弘, 梛野正人

日本消化器外科学会総会 Vol. 75回 page： P128 - 3 2020.12

　 PREV - NEXT 　

<HATTORI Norifumi>

Papers - HATTORI Norifumi